Varsha Gandhi, PhD, on Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Collyar: What's In It for Patients?

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mar

Today In Oncology

Varsha Gandhi, PhD, on Ibrutinib

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Collyar: What's In It for Patients?

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden

2026 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

Prostate Cancer: Low Testosterone Levels May Be Associated With Increased Risk of Progression During Surveillance

Stanford Names Leader for Drug Development and Precision Oncology